CBL — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL26101931	0.57	19/20
SCHEMBL26482271	0.57	19/20
SCHEMBL26482468	0.57	19/20
SCHEMBL26482276	0.57	19/20
SCHEMBL26484650	0.57	19/20
SCHEMBL26106013	0.55	19/20
SCHEMBL26483714	0.54	19/20
SCHEMBL30153197	0.54	19/20
SCHEMBL26106350	0.54	19/20
SCHEMBL27068282	0.52	19/20
SCHEMBL30311526	0.52	19/20
SCHEMBL26134044	0.50	19/20
SCHEMBL26481501	0.49	19/20
SCHEMBL26481502	0.49	19/20
SCHEMBL29254107	0.49	19/20
SCHEMBL26481512	0.48	19/20
SCHEMBL26481508	0.48	19/20
SCHEMBL26107325	0.47	19/20
SCHEMBL26484342	0.44	19/20
SCHEMBL26483535	0.43	19/20

Clinical trials — most relevant to CBL by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment	PHASE2	COMPLETED
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
5G-PEARL: Paxalisib in Malignant Brain Tumours	PHASE1/PHASE2	RECRUITING
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy	PHASE2	COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance	PHASE2	COMPLETED
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm	PHASE1	COMPLETED
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
A Study of TQB3820 in Patients With Hematological Malignancies	PHASE1	UNKNOWN
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas	PHASE1	COMPLETED
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery	EARLY_PHASE1	COMPLETED
Study of Tumor Samples From Patients With Lung Cancer	nan	COMPLETED
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population	nan	COMPLETED
Value of MicroRNA30a in Philadelphia Positive Leukemic Patients	nan	UNKNOWN
Prospective Monocentric Clinical-biological Database	nan	RECRUITING
Primary Resistance Mechanisms of ALK TKIs	nan	NOT_YET_RECRUITING
GENOMED4ALL: Improving MDS Classification and Prognosis by AI	nan	UNKNOWN
Testing of NBIA Genes: Analysis of Genetic Heterogeneity and Validation of Mitochondrial Markers for Assessing Causality of Sequence Variants.	nan	COMPLETED
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
Pure Florid and Pleomorphic Lobular Carcinoma in Situ of the Breast: Towards an Increasingly Uniform Management	nan	COMPLETED
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Molecular Disease Profile of Hematological Malignancies	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CBL binder may also engage these)

Protein	Name	Similarity
Q98TY6	—	1.000	Q98TY6 →
P22682	—	1.000	P22682 →
Q8K4S7	—	0.997	Q8K4S7 →
Q3TTA7	—	0.986	Q3TTA7 →
Q6NRE7	—	0.985	Q6NRE7 →
Q92625	—	0.984	Q92625 →
Q80U28	—	0.983	Q80U28 →
Q8BIZ1	—	0.983	Q8BIZ1 →
P49797	—	0.983	P49797 →
Q6GQL0	—	0.983	Q6GQL0 →
Q4KUS2	—	0.982	Q4KUS2 →
BCR	Breakpoint cluster region protein	0.982	landscape →
Q9Z1N9	—	0.982	Q9Z1N9 →
Q92622	—	0.981	Q92622 →
Q6PAJ1	—	0.981	Q6PAJ1 →
Q9TUG2	—	0.981	Q9TUG2 →
Q70E73	—	0.980	Q70E73 →
Q8R3V6	—	0.980	Q8R3V6 →
Q9Y2G1	—	0.980	Q9Y2G1 →
Q14CM0	—	0.980	Q14CM0 →
P0C6S7	—	0.979	P0C6S7 →
Q01826	—	0.979	Q01826 →
Q66H91	—	0.979	Q66H91 →
CBLB	E3 ubiquitin-protein ligase CBL-B	0.978	landscape →
Q9UPT6	—	0.978	Q9UPT6 →
P17863	—	0.978	P17863 →
Q8WXG6	—	0.978	Q8WXG6 →
Q96SB3	—	0.977	Q96SB3 →
Q60611	—	0.977	Q60611 →
Q7Z6G8	—	0.977	Q7Z6G8 →